TY - JOUR T1 - Decline, and Regional Disparities, in Medical Cocaine Usage in the United States JF - medRxiv DO - 10.1101/2020.08.25.20181065 SP - 2020.08.25.20181065 AU - Youngeun C. Armbuster AU - Brian N. Banas AU - Kristen D. Feickert AU - Stephanie E. England AU - Erik J. Moyer AU - Emily L. Christie AU - Sana Chughtai AU - Tanya J. Giuliani AU - Rolf U. Halden AU - Kenneth L. McCall AU - Brian J. Piper Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/31/2020.08.25.20181065.abstract N2 - Purpose Cocaine is a stimulant with a complex history that is used in otorhinolaryngological surgeries as a local anesthetic and vasodilator. There is extensive regulation in the United States for the storage and disposal of this Schedule II drug, potentially incentivizing health care professionals to avoid use. This descriptive study characterized medical cocaine use in the United States.Methods Retail drug distribution from 2002-2017 in units of grams of weight was extracted for each state from the Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System database, which reports on medical, research, and analytical-chemistry use. The percent of buyers (hospitals, pharmacies, providers) was obtained. Use per state, corrected for population, was determined. Available data on cocaine use, as reported by the Medicare and Medicaid programs for 2013 – 2017, also were examined.Results Medical cocaine use in the US, measured on the basis of mass, decreased 62.5% from 2002 to 2017. Hospitals accounted for 84.9% and practitioners for 9.9% of cocaine distribution in 2017. The number of pharmacies nationwide carrying cocaine dropped by 69.4% to 206. The percent of all US hospitals, practitioners, and pharmacies that carried cocaine in 2017 was 38.4%, 2.3%, and 0.3%, respectively. There was a seven-fold difference in distribution per state in 2002 (South Dakota = 76.1 mg/100 persons, Delaware = 10.1 mg/100 persons). Similarly, there was a ten-fold regional disparity observed for 2017. Relative to the average state, those reporting the highest values (Montana = 20.1 and North Dakota = 24.1 mg/100 persons), were significantly elevated. Cocaine use within the Medicare and Medicaid programs was negligible.Conclusion Medical cocaine use across the United States exhibited a pronounced decline over a fifteen-year period. If this pattern continues, licit cocaine will soon become an obscure pharmacological relic of interest only to analytical chemists and medical historians.Key PointsQuestion: How has medical use of cocaine, a local anesthetic and vasoconstrictor administered for otorhinolaryngological surgeries and some diagnostic procedures, changed in the United States?Findings: Cocaine usage, as reported to the Drug Enforcement Administration has undergone a pronounced (62.5%) decline over the past fifteen-years, while some pronounced regional differences were noted.Meaning: Although cocaine has played a key role in the history of anesthesia, the development of safer and non-controlled alternatives may continue to supplant this agent in contemporary use.Competing Interest StatementBJP is supported by an osteoarthritis research grant from Pfizer. The other authors have no relevant disclosures.Clinical TrialThis retrospective descriptive study was not registered.Funding StatementNo external funding in support of this project was received. BJP is supported by Pfizer and the Health Resources Services Administration.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of the University of New England and Geisinger approved these procedures as exempt.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Drug Enforcement Administration's data is publically available. https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html ER -